Research Article Details
| Article ID: | A16189 |
| PMID: | 28511168 |
| Source: | Wiad Lek |
| Title: | [The nonalcoholic steatohepatitis influence on the course and progression of ischemic heart disease]. |
| Abstract: | INTRODUCTION: Nonalcoholic steatohepatitis (NASH) can be considered a risk factor of progression of diseases associated with atherosclerosis, especially ischemic heart disease (IHD) with a high probability of early myocardial infarction (MI). AIM: To study the peculiarities and nature of ischemic heart disease clinical picture in patients with concomitant NASH. MATERIALS AND METHODS: The study involved 58 patients with ischemic heart disease. The nature of ischemic heart disease according to outpatients was evaluated, an assessment of ECG, echocardioscopy changes and Holter-monitoring was performed. RESULTS: The ischemic heart disease and concomitant NASH was observed only in young and middle age patients, among whom 16 (61.5%) revealed the presence of visceral obesity type. The presence of this synthropy is accompanied by an aggressive course of coronary heart disease with early MI development. According to Seattle Angina Questionnaire scale is case of IHD with NASH combination more limitation of physical activity, less pleasure treatment, worse perception of the disease and a significant reduction in the life quality of patients were noted. The nature of myocardium bioelectric activity disorders did not differ in the comparison group and matched the angina functional class and myocardial infarction consequences. CONCLUSIONS: The presence of visceral obesity, NASH causes early and aggressive course of ischemic heart disease, which is accompanied by a high risk of MI and reduces the patients' quality of life. |
| DOI: |
| Strategy ID | Therapy Strategy | Synonyms | Therapy Targets | Therapy Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |
| I07 | 1936 | Arteriosclerosis | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 | disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease | Details |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress | |
|---|---|---|---|---|---|---|---|
| D248 | Obeticholic Acid | Chemical drug | DB05990 | NR1H4 activator; NR1H4 agonist; FXR agonist | Enhance lipid metabolism | Approval rejected | Details |
| D328 | Serine | Chemical drug | DB00133 | SRR | Improve insulin resistance | Under clinical trials | Details |
| D579 | Emfilermin | Miscellany | -- | adipocytes | Enhance lipid metabolism | Under investigation | Details |
| D083 | CLA | Chemical drug | DB01211 | KCNH2; SLCO1B1; SLCO1B3 | -- | Under clinical trials | Details |